<DOC>
	<DOCNO>NCT01694420</DOCNO>
	<brief_summary>This multicenter , single arm , 48-week open-label study FDC ELV/COBI/FTC/TDF [ Stribild ] acute HIV infection . Study sit member Duke-UNC Acute HIV Infection Study Consortium . Participants enrol 96 week . Clinical care study drug ( ELV/COBI/FTC/TDF ) provide first 48 week . After week 48 , clinical care study drug provide week 96 . A study participant suppress week 48 continue FDC ELV/COBI/FTC/TDF . The primary hypothesis daily fixed-dose combination elvitegravir ( ELV ) , cobicistat ( COBI ) , emtricitabine ( FTC ) , tenofovir disoproxil fumarate ( TDF ) rapidly reduce viral replication &lt; 50 copy RNA/ml participant acute HIV infection . The secondary hypothesis consider 1 ) virologic response rate measure plasma HIV RNA level non-inferior superior historical group participant PHI cohort treat EFV/FTC/TDF , 2 ) compare historical control treat EFV/FTC/TDF , plasma HIV RNA decrease rapidly PHI participant treat ELV/COBI/FTC/TDF , 3 ) compare historical control treat EFV/FTC/TDF , immune activation measure proportion CD4+ CD8+ cell express HLA-DR CD38+ decrease rapidly PHI participant treat ELV/COBI/FTC/TDF , 4 ) subset participant sample obtain compartment gastrointestinal tract , lymphoid tissue ass change time parameter HIV-1 RNA , immunologic response HIV , tissue anatomic reservoir . We hypothesize treatment ELV/COBI/FTC/TDF demonstrate improve viral clearance compartment compare historical control treat EFV/FTC/TDF . 5 ) subset participant remain suppressed therapy , rest CD4 cell replication-competent HIV-1 ( latent reservoir ) quantitated compare similar measurement PHI participant treat EFV/FTC/TDF . In addition , compare result measure HIV-1 infect participant treat 6 ) ELV/COBI/FTC/TDF well tolerate , proportion participant require treatment modification less observed participant treat EFV/FTC/TDF .</brief_summary>
	<brief_title>Treatment Acute HIV Infection With Quad Fixed-dose Combination ( FDC ) Tablet</brief_title>
	<detailed_description>None desire</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Cobicistat</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Elvitegravir , Cobicistat , Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<criteria>Acute HIV infection define : 1 . A positive 4th generation HIV Ag/Ab Combination Assay HIV RNA ( NAAT viral load ) one follow within 30 day study entry : negative HIV rapid test negative/indeterminate Western Blot OR 2 . A negative indeterminate HIV antibody , antigen , nucleic acid amplification test ( NAAT ) one follow within 30 day study entry : A detectable HIV nucleic acid blood confirm second NAAT Positive p24 antigen A positive HIV antibody test accord standard criterion obtain within 45 day initial negative indeterminate HIV antibody , antigen , nucleic acid amplification . 1 . Acute HIV Infection ( define ) within 30 day study entry . 2 . Age &gt; 18 year . 3 . ARTnaive ( &lt; 14 day previous antiretroviral treatment . Exceptions : Postexposure prophylaxis ( PEP ) participant document HIVnegative least 3 month completion PEP . 4 . Lab value within 30 day prior study entry : 1 . Absolute neutrophil count &gt; 500/mm3 2 . Hemoglobin &gt; 8.5 g/dL men &gt; 8.0 g/dL woman 3 . Platelet count &gt; 50,000/mm3 4 . AST ( SGOT ) &gt; .2.5 x ULN 5 . ALT ( SGPT ) &gt; .2.5 x ULN 6 . Total bilirubin &lt; 2.5 x ULN 7 . Calculated creatinine clearance ( CockcroftGault formula ) &gt; 70mL/min : 5 . For woman reproductive potential , negative pregnancy test within 72 hour prior initiate antiretroviral study medication . Reproductive potential define female reach menarche postmenopausal least 24 consecutive month , undergone surgical sterilization . 6 . Female study participant must use reliable form barrier contraception , condom , even also use method birth control . All participant must continue use contraception 12 week stop study medication . Acceptable method barrier contraception include : condom ( male female ) , diaphragm , cervical cap . These use alone tandem hormonal IUD method . 7 . Ability willingness participant give write informed consent . 1 . Women pregnant breastfeeding . 2 . Women positive pregnancy test prior study drug administration . 3 . Men sex woman , woman reproductive potential unwilling unable use acceptable , reliable barrier method contraception entire study period 12 week afterwards . 4 . Use immunomodulators ( e.g. , interleukin , interferon , cyclosporine ) , HIV vaccine , systemic cytotoxic chemotherapy , investigational therapy within 30 day study entry ( Prednisone 10 mg QD less permit . 5 . Known allergy/sensitivity study drug 6 . Difficulty swallow pill 7 . Inability communicate effectively study personnel 8 . Incarceration ; prisoner recruitment participation permit 9 . Active drug alcohol use , opinion site investigator , would interfere participation study 10 . Any active psychiatric illness , opinion investigator , could confound analysis neurological examination neuropsychological test result 11 . Active brain infection ( except HIV1 ) , brain neoplasm , spaceoccupying brain lesion require acute chronic therapy 12 . Serious illness require systemic treatment and/or hospitalization patient either complete therapy clinically stable therapy least 7 day prior study entry 13 . Known cardiac conduction disease 14 . Prior treatment experimental drug within 30 day initiate study treatment 15 . Unable discontinue current medication exclude study treatment 16 . Life expectancy less twelve month 17 . Acute Viral Hepatitis , include , limited , Hepatitis A , B , C 18 . Chronic Hepatitis B Infection document detectable serum Hepatitis B surface antigen ( HBsAg ) plasma HBV DNA 19 . Calculated creatinine clearance ( CockcroftGault formula ) &lt; 70mL/min</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>